A Phase I Trial of ZIO-101 in Solid Tumors

Phase 1

Completed

• Conditions: Solid Tumors
• Interventions: Drug: ZIO-101 (Darinaparsin)

• Registration Number: NCT00591396
• Lead Sponsor: Alaunos Therapeutics

Brief Summary

A Phase I Trial of ZIO-101 (Darinaparsin) in Solid Tumors

Detailed Description

Not available

Study Timeline

• Study Start: 2005-07
• Study First Submitted: 2007-12-26
• Study First Submitted QC: 2008-01-10
• Study First Posted: 2008-01-11
• Primary Completion: 2008-07
• Study Completion: 2008-07
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-18
• Last Update Posted: 2012-07-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	ZIO-101 (Darinaparsin)	-

Primary Outcome Measures

Name	Time	Method
toxicities	6 months

Secondary Outcome Measures

Name	Time	Method
pharmacokinetics	6 months